Search Selank side effects and nearly every page says the same thing: none reported. The trials behind that sentence are Russian-language, and Western randomized trials of Selank number zero.
The short answer. Western randomized trials of Selank number zero, so no adverse-event table exists in English.
- Russia approved Selank as 0.15% nasal drops in 2009, but those trial documents are largely outside PubMed.
- The only Western human study is a 2020 brain scan of 52 healthy adults, and it was not a safety study.
- Rat work shows changes in gut tissue morphology and in cytokines including IL-1beta, IL-6 and TNF-alpha.
Selank is widely sold as side-effect free. That claim has thin backing. Russia approved it for anxiety in 2009. Those trial papers are not in PubMed. Western randomized trials number zero. No long-term human safety study has been published in English.
What are the side effects of Selank?
Nobody in the West has measured them. That is the answer, and it is not the same as saying there are none.
Russia approved Selank as nasal drops for generalized anxiety disorder in 2009. The registered strength is 0.15%, or 1.5 mg per mL. A safety record exists inside that approval. It sits in Russian-language documents that are largely outside PubMed, so you cannot open it and check it.
The Western human record is one study. A 2020 brain-imaging paper scanned 52 healthy adults and saw connectivity shifts inside 20 minutes. It was built to measure brain networks, not harm. There was no adverse-event follow-up over weeks, no bloodwork series, no control group tracked for months.
| Type of safety evidence | What exists for Selank in English |
|---|---|
| Randomized placebo-controlled trials | Zero |
| Long-term human dosing study | None published |
| Post-marketing reports you can retrieve | None in English |
| Drug interaction studies | None published |
| Pregnancy, pediatric, liver or kidney data | None published |
| Acute human exposure | One imaging study, 52 adults |
Across the whole compound there are about 4 peer-reviewed Western studies. Most are in rats. The Selank anxiety trials page goes through the approval evidence in detail.
Why "no reported side effects" is not a safety finding
A side effect gets reported when someone is watching for it. Two things have to be in place. A trial has to collect adverse events on a form. A regulator has to publish them.
For Selank, neither step produced a document you can read. So the phrase "no reported side effects" describes the reporting, not the compound.
Russia approved Selank for generalized anxiety disorder in 2009. The trials behind that call used medazepam, a benzodiazepine. But those trials are not in PubMed.
wheretobuypeptides.org, Selank anxiety trialsThat matters twice over here. Medazepam is a benzodiazepine, and the usual reason to compare a new anxiety drug against one is sedation and dependence. Russian summaries say Selank did not produce them. We cannot open the tables that would show it.
The claim most often repeated about Selank safety rests on studies nobody outside that literature can audit. Treat it as unverified, not as disproven.
The site's Selank complete guide sets out what the approval does and does not rest on.
What the animal studies actually flagged
The rat work is the only place where anyone measured tissue. It is small, and it is not a toxicology program. Two findings are worth naming because they are the kind of thing a human safety study would follow up.
- Gut tissue. Mukhina and colleagues, in Bulletin of Experimental Biology and Medicine in 2020, looked at the large intestine of rats under chronic restraint stress and treated with Selank. The endpoint was morphology, meaning the structure of the tissue itself.
- Immune signaling. Yasenyavskaya and colleagues, in 2021, measured cytokines in a "social" stress model. The panel included IL-1β, IL-6, TNF-α and TGF-β1. Selank shifted them.
- Behavior in withdrawal. Konstantinopolsky and colleagues, in 2022, used a morphine-withdrawal model in rats. Aversive, anxiety-like signs fell 39.6%. The reported administration was 0.3 mg/kg, into the abdomen.
Morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with Selank.
Mukhina et al., Bulletin of Experimental Biology and Medicine, 2020 (title)Read that title as a safety note, not only a benefit note. A peptide that changes cytokine levels and gut tissue structure in a rat is a peptide with a biological reach. Nobody has checked what that reach does in a person over a 14-day course, let alone a year.
One more caution about mechanism pages. Work by Vyunova and colleagues on the GABA-receptor system, published in 2023, studied synthetic corticotropins, the Semax family, not Selank. It is often cited as if it were the same molecule. The tuftsin and GABAergic mechanism page separates the two.
Selank
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Route changes the risk, and the route data is missing
Selank's clinical route is the nose. The Russian approval is a nasal form, and the trials behind it used the nose.
No published figure exists for how much of a nasal dose is absorbed. That single gap undercuts every safety statement carried over from the Russian label, because a label's safety profile belongs to a specific route and a specific strength.
The research market often sells vials intended for injection. We found no published human study of Selank given under the skin. So the exposure people are creating is not the exposure the approval covered. The nasal spray page and the dosage page lay out what each cited study actually administered, and what it left blank.
Rodent papers state their amounts plainly, including 100 µg/kg/day in stress models. Those are animal numbers with an animal route. They are reporting, not a human protocol, and they do not convert.
The risk that is not pharmacology
For a compound with no published human toxicity signal, the larger practical hazard is the vial, not the molecule.
- Purity. A research vial is not a pharmacy product. What is in it is whatever the third-party test says, if there is one. See how to read a certificate of analysis.
- Identity. Selank is a 7-amino-acid tuftsin analog. Mass spectrometry on the COA is what ties the powder to that sequence.
- Handling. Peptide degradation is driven by temperature and time, covered on the storage page.
- Sport testing. The World Anti-Doping Agency republishes its Prohibited List each year. We do not state Selank's status here. Anyone in tested sport should read the current edition themselves.
Legal status is separate again and varies by country. The legality page covers it.
What would actually count as safety evidence
Here is the short list of things that do not exist yet. Each one is checkable, which is the point.
- A placebo-controlled Western trial with an adverse-event table.
- Any published human pharmacokinetic study by the nasal route.
- Repeat-dose bloodwork in people, including liver and kidney panels.
- An immune panel in humans, given what the rat cytokine work showed.
- A registry or post-marketing summary in English from the 2009 approval onward.
Until at least the first two exist, "Selank is well tolerated" is a claim about the absence of records. It is not a claim about the absence of harm.
The benefits page applies the same test to the other half of the marketing.
Selank
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Western randomized trials of Selank number zero, so no adverse-event table exists in English.
- Russia approved Selank as 0.15% nasal drops in 2009, but those trial documents are largely outside PubMed.
- The only Western human study is a 2020 brain scan of 52 healthy adults, and it was not a safety study.
- Rat work shows changes in gut tissue morphology and in cytokines including IL-1beta, IL-6 and TNF-alpha.
- No published figure exists for how much of a nasal dose is absorbed, and no human study used injection.
- For an unstudied compound, vial purity and third-party testing are the practical risk, not the pharmacology.
What we're watching
What Selank safety data actually shows
Frequently asked questions
Does Selank cause drowsiness?
Russian summaries say it did not sedate, which is why it was compared against medazepam, a benzodiazepine. Those comparison tables are not in PubMed, so we cannot check them. Animal work also describes reduced anxiety-like behavior without sedation. No Western trial has measured alertness in people over time.
Is Selank safe for long-term use?
Nobody has published a long-term human safety study in English. The compound has been registered in Russia since 2009, but the follow-up data from that period is not retrievable outside the Russian literature. Long-term safety here is unknown, not established.
Can Selank affect the immune system?
It is plausible and unmeasured in people. Selank is a tuftsin analog, and tuftsin is an immune peptide. Yasenyavskaya and colleagues, in 2021, reported that Selank shifted IL-1beta, IL-6, TNF-alpha and TGF-beta1 in a rat social-stress model. No human immune panel has been published.
Does Selank cause withdrawal or dependence?
No published human study has tested for it. A 2022 paper by Konstantinopolsky and colleagues used a morphine-withdrawal model in rats and reported a 39.6% drop in aversive signs. That is a study of another drug's withdrawal, not of Selank dependence.
Is Selank banned in sport?
We do not state its status. The World Anti-Doping Agency updates its Prohibited List annually, and the current edition is the only reliable source. Anyone subject to testing should read that list directly rather than rely on a vendor page.
Why do vendor pages say Selank has no side effects?
Because no accessible study collected them. Russian trials exist behind the 2009 approval, but they sit outside PubMed. An empty adverse-event record in English is an artifact of who ran the trials and where they published, not evidence of a clean profile.
References
- Russian regulatory communications. (2009 onward.) Russian Ministry of Health approval of Selank as a nasal-drop formulation for generalized anxiety disorder. (Cited for regulatory context; primary trial documents are largely Russian-language and outside PubMed.) Russian Ministry of Health https://www.rosminzdrav.ru/
- Panikratova, Y. R., Lebedeva, I. S., Sokolov, O. Y., et al. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X
- Mukhina, A. Y., Mishina, E. S., Bobyntsev, I. I., et al. (2020). Morphological changes in the large intestine of rats subjected to chronic restraint stress and treated with Selank. Bulletin of Experimental Biology and Medicine, 169(2), 281–285. https://doi.org/10.1007/s10517-020-04868-9
- Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., et al. (2021). The influence of Selank on the level of cytokines under the conditions of "social" stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162–167. https://doi.org/10.2174/1574884715666200704152810
- Konstantinopolsky, M. A., Chernyakova, I. V., & Kolik, L. G. (2022). Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bulletin of Experimental Biology and Medicine, 173(6), 730–733. https://doi.org/10.1007/s10517-022-05624-x
- Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., et al. (2023). Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221
- World Anti-Doping Agency. The Prohibited List 2026. https://www.wada-ama.org/en/prohibited-list